Jafron Biomedical Co

Jafron Biomedical Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co (300529.SZ) as of Oct 15, 2026 is 13.67 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 19.42 % — a change of -29.59% (lower).

EBIT/Assets

13.67 %

YoY

-29.59%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co is 2025 13.67 % . Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co was 2024 19.42 % . It decreases by -29.59% lower compared to the previous year.

The Jafron Biomedical Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
23.21 CNY
Jan 1, 2019
27.27 CNY
Jan 1, 2020
32.78 CNY
Jan 1, 2021
29.48 CNY
Jan 1, 2022
19.02 CNY
Jan 1, 2023
9.81 CNY
Jan 1, 2024
19.42 CNY
Jan 1, 2025
13.67 CNY
The Jafron Biomedical Co EBIT/Assets history
YEAREBIT/AssetsYoY
13.67 %-29.59%
19.42 %+97.93%
9.81 %-48.41%
19.02 %-35.49%
29.48 %-10.07%
32.78 %+20.19%
27.27 %+17.49%
23.21 %+19.13%
19.48 %+8.86%
17.90 %-46.88%
33.69 %+4.35%
32.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co Ltd is a China-based health care company headquartered in Zhuhai. The company focuses on the research, development, production, and sale of hemoperfusion products. It went public on August 2, 2016, with its stock listed under ticker 300529.SZ and ISIN CNE100002995. Jafron employs 3,003 full-time staff and operates within the health care sector. Its products include disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resin bandages. These products are used in treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. Jafron's products are distributed across more than 3,000 hospitals in all 31 provinces of China. The company's website is https://www.jafron.com/. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co is 13.67 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Jafron Biomedical Co changed from 19.42 % to 13.67 %, representing a -29.59% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Jafron Biomedical Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Jafron Biomedical Co